Research programme: HIV integrase inhibitors - Amgen

Drug Profile

Research programme: HIV integrase inhibitors - Amgen

Alternative Names: HIV integrase inhibitors research programme - Amgen

Latest Information Update: 09 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tularik
  • Class
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 09 Dec 2003 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 12 Jul 2001 Preclinical development for HIV infections treatment in USA (Unknown route)
  • 21 Oct 1999 Proteus International has merged with Therapeutic Antibodies to form Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top